Value of Abciximab in Patients With AMI Undergoing Primary PCI After Clopidogrel Pretreatment (BRAVE 3)

• Status: Completed
• Trial end date: 2008-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess whether abciximab is associated with additional benefit in patients with AMI treated with PCI after high dose clopidogrel loading.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Deutsches Herzzentrum Muenchen
• Collaborator: Technische Universität München
• Treatments: Abciximab; Antibodies, Monoclonal; Calcium heparin; Clopidogrel; Heparin; Immunoglobulin Fab Fragments

Criteria

Inclusion Criteria:

• Patients presenting with ST-Elevation acute myocardial infarction within 24 hours from the onset of symptoms

Exclusion Criteria:

• Age >80 years

• Malignancies

• Cardiogenic shock

• Prolonged cardio-pulmonary resuscitation

• Increased risk of bleeding

• Relevant hematologic deviations (hemoglobin <100 g/L or hematocrit <34%, platelet count <100 x 10^9 /L or platelet count >600 x 10^9 /L)

• Known allergy to the study medication

• Pregnancy (present or suspected)